Notes from the Field: Posttreatment Lesions After Tecovirimat Treatment for Mpox — New York City, August–September 2022
Authors:
- Leah SeifuLSLeah Seifu
- Elizabeth GarciaEGElizabeth Garcia
- Tristan D. McPhersonTMTristan D. McPherson
- Maura LashMLMaura Lash
- Karen A. AlroyKAKaren A. Alroy
- Mary FooteMFMary Foote
- Ellen H. LeeELEllen H. Lee
- Jeffrey KwongJKJeffrey Kwong
- Asa RadixARAsa Radix
- Paul RiskaPRPaul Riska
- Jason ZuckerJZJason Zucker
- Sarah ZuercherSZSarah Zuercher
- 28 April 2023
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (17) , 471-472
Abstract
This report describes treatment of lesions following completion of tecovirimat therapy for mpox.Keywords
This publication has 3 references indexed in Scilit:
- Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19JAMA Network Open, 2022
- Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future ConsiderationsNew England Journal of Medicine, 2022